{"id":"W4409077337","doi":"10.1136/bmjgast-2024-001615","title":"Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial","year":2025,"lang":"en","type":"article","venue":"BMJ Open Gastroenterology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Western University; Ottawa Hospital; University of British Columbia; University of Ottawa; Montreal General Hospital; McMaster University; Population Health Research Institute; University of Alberta; University of Calgary","funders":"H2020 European Research Council; University of California, San Diego; Samsung; Genentech; Crohn's and Colitis Canada; Shionogi; Celltrion; Celgene; Teva Pharmaceutical Industries; Janssen Pharmaceuticals; Gilead Sciences; Sanofi; National Institute of Diabetes and Digestive and Kidney Diseases; Tillotts Pharma; Amgen; Pfizer; Patient-Centered Outcomes Research Institute; Eli Lilly and Company; Bristol-Myers Squibb; Mylan; GlaxoSmithKline","keywords":"Medicine; Inflammatory bowel disease; Complete remission; Randomized controlled trial; Open label; Internal medicine; Ulcerative colitis; Surgery; Disease; Chemotherapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.07719591,0.006169316,0.009253353,0.002718834,0.002622149,0.005689949,0.003661132,0.009775712,0.0358576],"category_scores_gemma":[0.07166657,0.003174552,0.005991562,0.003602805,0.006164778,0.004335553,0.002581659,0.008238163,0.009112099],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00388427,"about_ca_system_score_gemma":0.01300977,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001209578,"about_ca_topic_score_gemma":0.002786653,"domain_scores_codex":[0.928309,0.05637756,0.005574745,0.003254808,0.004014584,0.002469229],"domain_scores_gemma":[0.9750159,0.009354623,0.004730289,0.003422755,0.004004499,0.003472],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8262545,0.008920765,0.001330038,0.06445818,0.004933501,0.0005420758,0.001338512,0.002367665,0.002752142,0.01601314,0.02503355,0.04605579],"study_design_scores_gemma":[0.9132382,0.01985827,0.002306885,0.01160854,0.00177739,0.0002211416,0.0002511974,0.002784113,0.0008716817,0.007942754,0.03897347,0.0001663204],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.001308523,0.0005815121,0.001645222,0.0003705024,0.0003941457,0.9943181,0.0006460362,0.00006968646,0.0006662331],"genre_scores_gemma":[0.002338343,0.0001737399,0.003546184,0.0002833237,0.00007752624,0.9932188,0.0001300485,0.000006194045,0.0002258817],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.07719591,"threshold_uncertainty_score":0.4082559,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01527880204060522,"score_gpt":0.32751507026901,"score_spread":0.3122362682284048,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}